Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Sign up for one of our free Webinars to learn about basic and advanced science topics, get tips and techniques for your lab, or find out more about new technologies and products. Webinars cover educational topics in life science research, drug discovery, clinical research, applied sciences, clinical and molecular diagnostics, and more. Live presentations include the opportunity to ask questions via chat. Don't worry if you missed a presentation date—past Webinars are available for on-demand viewing. 

Upcoming Webinars

Resetting Expectations for CAR-T Potency Assessment – A Novel Target Cell Killing-Based Approach

Potency assays are an essential aspect of analyses of biotherapeutics, including CAR-T therapeutics. The potency assay format that will be used as a release assay for CTM (in a QC environment) needs to be as accurate, precise and robust as possible. Developing a robust potency assay for CAR-T therapeutics can be a long and complicated process. The mechanism of action of CAR-T cells – dubbed ‘living drugs’ – in-vivo is multi-faceted. Currently, target-cell killing and cytokine induction are two of the more prominent measures indicative of CAR-T potency in the cell therapy field. This webinar will provide the rationale and data that supports transitioning from current interpolation-based cytokine induction assays, with minimal number of dilutions (one), to full-curve analyses based upon MOA-reflective cellular responses. 

Avinash Chinthala, Scientist, CMC Analytical Development, Precision BioSciences Inc.

Wednesday, October 5, 2022 @ 10am CDT / 11am EDT / 4pm London / 5pm Amsterdam-Paris
Thursday, October 6, 2022 @ 12pm Singapore / 3pm Sydney / 1pm Seoul / 9:30am New Delhi

Register Here:

Wednesday, October 5Thursday, October 6

Keeping it Real: Why P450 Assays are Required to Predict Human Drug Responses Using Liver-on-a-Chip

Despite billions in investment, most drugs never reach the market because preclinical experiments fail to predict human effects. Standard in vitro assays lack physiological relevance, whilst animal models lack human relevance. By better replicating human organs and tissues in the laboratory, PhysioMimix™ Organ-on-a-chip systems address these limitations. In this webinar, Dr. Darren Heywood from Promega will introduce assays optimized for 3D cell culture, including a suite of P450-Glo™ Assays. Dr Atefeh Mobasseri from CN Bio, will then discuss the use of Promega P450-Glo™ assay kit as a critical step in cell quality control to assess the metabolic activity of a liver-on-a-chip model. 

Darren Heywood, PhD, Product Manager – Cell Health, Promega UK
Atefeh Mobasseri, PhD, Field Application Scientist, CN-Bio

Tuesday, October 11, 2022 @ 1pm London / 2pm Amsterdam-Paris
Tuesday, October 11, 2022 @ 1pm CDT / 2pm EDT
Wednesday, October 12, 2022 @ 12pm Singapore / 3pm Sydney / 1pm Seoul / 9:30am New Delhi

Register Here:

October 11 - 1pm BST/2pm CESTOctober 12 - 12pm SGT/3pm AEDT/1pm KSTOctober 11 - 1pm CDT / 2pm EDT

Current Gold Standards for MSI Testing and the Clinical Relevance of the MSI-H Biomarker

Historically MSI has been used to screen for Lynch syndrome, a dominant hereditary cancer propensity. Recently, MSI status has been rediscovered as a biomarker for immunotherapeutic response, making MSI status an increasingly relevant tool for genetics and immuno-oncology applications. In this webinar, we will discuss MSI testing gold standards and compare the different methods that are currently being used for MSI testing for mismatch repair deficient (dMMR) tumors. We will also discuss the clinical relevance of the MSI-H biomarker focusing on the pathological and epidemiological characteristics of MSI-H/dMMR tumors, and the role of MSI testing in Lynch syndrome screening, colorectal cancer patient prognosis, and immunotherapy treatment.

Emily A Teslow, PhD, Medical Science Liaison, Promega Corporation

Wednesday, October 19, 2022 - 10am CDT / 11am EDT / 4pm London / 5pm Amsterdam-Paris
Thursday, October 20, 2022 - 12pm Singapore / 3pm Sydney / 1pm Seoul / 9:30am New Delhi

Register Here:

Wednesday, October 19 Thursday, October 20

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up

Search On-Demand Webinars